Literature DB >> 19843155

The Drooling Impact Scale: a measure of the impact of drooling in children with developmental disabilities.

Susan M Reid1, Hilary M Johnson, Dinah S Reddihough.   

Abstract

AIM: To describe the development and clinimetric properties of a new scale to evaluate changes in the impact of drooling in children with developmental disabilities.
METHOD: After examining the properties of potential items, 10 items were retained for inclusion in the final Drooling Impact Scale. The clinimetric properties of the scale were evaluated using data from two convenience samples of children attending a saliva-control clinic: a stable group (n=31, 22 males, nine females; mean age 10y 7mo, SD 4y 5mo, range 3y 6mo-18y 3mo; cerebral palsy [CP] n=17, intellectual disability n=10; non-ambulatory n=13, nonverbal n=12) and an intervention group (n=49, 29 males, 20 females; mean age 11y, SD 3y 6mo, range 3y 4mo-16y 10mo; CP n=31, intellectual disability n=15; non-ambulatory n=27, nonverbal n=28). To assess validity, changes in scores on the Drooling Impact Scale over time were compared with a carer's global rating of change using Pearson's correlations and t-tests. A concordance correlation coefficient was used to compute the level of agreement between assessments 1 month apart in stable children. Effect size, standardized response mean, Guyatt responsiveness statistic, and an unpaired t-test were used to estimate responsiveness.
RESULTS: The correlation between the global rating and change in Drooling Impact Scale scores was 0.69 (p<0.001). The concordance correlation coefficient was 0.85. An effect size of 1.8, standardized response mean of 1.5, Guyatt responsiveness statistic of 1.4, and mean group difference of 23.5 (95% confidence interval 17.4-29.6) were obtained.
INTERPRETATION: The Drooling Impact Scale is a valid and reliable subjective measure that is responsive to change.

Entities:  

Mesh:

Year:  2009        PMID: 19843155     DOI: 10.1111/j.1469-8749.2009.03519.x

Source DB:  PubMed          Journal:  Dev Med Child Neurol        ISSN: 0012-1622            Impact factor:   5.449


  15 in total

Review 1.  Gastrointestinal Dysfunction in Parkinson's Disease.

Authors:  Delaram Safarpour; Kaveh Sharzehi; Ronald F Pfeiffer
Journal:  Drugs       Date:  2022-01-25       Impact factor: 9.546

2.  Anticholinergic treatment for sialorrhea in children: A systematic review.

Authors:  Peng You; Julie Strychowsky; Karan Gandhi; Breanna A Chen
Journal:  Paediatr Child Health       Date:  2021-08-27       Impact factor: 2.600

3.  Oral glycopyrrolate for the treatment of chronic severe drooling caused by neurological disorders in children.

Authors:  Marian L Evatt
Journal:  Neuropsychiatr Dis Treat       Date:  2011-09-20       Impact factor: 2.570

4.  Intrathecal baclofen therapy in paediatrics: a study protocol for an Australian multicentre, 10-year prospective audit.

Authors:  Kirsty Stewart; Gavin Hutana; Megan Kentish
Journal:  BMJ Open       Date:  2017-06-21       Impact factor: 2.692

5.  Changes in severity and impact of drooling after submandibular gland botulinum neurotoxin A injections in children with neurodevelopmental disabilities.

Authors:  Karen Van Hulst; Jan Jw Van Der Burg; Peter H Jongerius; Alexander Ch Geurts; Corrie E Erasmus
Journal:  Dev Med Child Neurol       Date:  2019-11-14       Impact factor: 5.449

6.  The sublingual use of atropine in the treatment of clozapine-induced sialorrhea: A systematic review.

Authors:  Thomas Van der Poorten; Marc De Hert
Journal:  Clin Case Rep       Date:  2019-09-27

7.  A Cross-Sectional Study of Nemaline Myopathy.

Authors:  Kimberly Amburgey; Meryl Acker; Samia Saeed; Reshma Amin; Alan H Beggs; Carsten G Bönnemann; Michael Brudno; Andrei Constantinescu; Jahannaz Dastgir; Mamadou Diallo; Casie A Genetti; Michael Glueck; Stacy Hewson; Courtney Hum; Minal S Jain; Michael W Lawlor; Oscar H Meyer; Leslie Nelson; Nicole Sultanum; Faiza Syed; Tuyen Tran; Ching H Wang; James J Dowling
Journal:  Neurology       Date:  2021-01-04       Impact factor: 9.910

8.  The drooling reduction intervention trial (DRI): a single blind trial comparing the efficacy of glycopyrronium and hyoscine on drooling in children with neurodisability.

Authors:  Jeremy R Parr; Emma Weldon; Lindsay Pennington; Nick Steen; Jane Williams; Charlie Fairhurst; Anne O'Hare; Raj Lodh; Allan Colver
Journal:  Trials       Date:  2014-02-17       Impact factor: 2.279

9.  Drooling Reduction Intervention randomised trial (DRI): comparing the efficacy and acceptability of hyoscine patches and glycopyrronium liquid on drooling in children with neurodisability.

Authors:  Jeremy R Parr; Emma Todhunter; Lindsay Pennington; Deborah Stocken; Jill Cadwgan; Anne E O'Hare; Catherine Tuffrey; Jane Williams; Mike Cole; Allan F Colver
Journal:  Arch Dis Child       Date:  2017-11-30       Impact factor: 3.791

10.  Can muscle vibration be the future in the treatment of cerebral palsy-related drooling? A feasibility study.

Authors:  Emanuele F Russo; Rocco S Calabrò; Patrizio Sale; Filomena Vergura; Maria C De Cola; Angela Militi; Placido Bramanti; Simona Portaro; Serena Filoni
Journal:  Int J Med Sci       Date:  2019-09-20       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.